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Successful allogeneic hematopoietic stem cell transplantation (HSCT) depends not only
on good HLA match but also on T-cell mediated graft-versus-leukemia (GvL) effect. Nat-
ural killer (NK) cells are able to kill malignant cells by receiving activation signal from the
killer-cell immunoglobulin-like receptors (KIR) recognizing HLA molecules on a cancer cell.
It has been recently reported that the risk of relapse in allogeneic hematopoietic stem
cell transplantation (HSCT) is reduced in acute myeloid leukemia (AML) patients whose
donors have several activating KIR genes or KIR B-motifs in unrelated donor setting, obvi-
ously due to enhanced GvL effect by NK cells.We studied the effect on relapse rate of donor
KIR haplotypes in the HLA-identical adult sibling HSCT, done in a single center, in Helsinki
University Central Hospital, Helsinki, Finland. Altogether, 134 patients with 6 different diag-
noses were identified. Their donors were KIR genotyped using the Luminex and the SSP
techniques. The clinical endpoint, that is, occurrence of relapse, was compared with the
presence or absence of single KIR genes. Also, time from transplantation to relapse was
analyzed.The patients with AML whose donors have KIR2DL2 or KIR2DS2 had statistically
significantly longer relapse-free survival (P =0.015). Our data support previous reports that
donors with KIR B-haplotype defining genes have a lower occurrence of relapse in HSCT
of AML patients. Determination of donor KIR haplotypes could be a useful addition for a
risk assessment of HSCT especially in AML patients.
Keywords: NK cells, KIR, HLA, graft versus tumor effect, transplantation immunology
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is an
established curative treatment for many hematological malignan-
cies. The outcome of HSCT is strongly influenced by the genetic
differences between donor/recipient pairs (1). Genetic similar-
ity or identity in the HLA genes in the major histocompatibility
complex on chromosome 6, affects the incidence of graft-versus-
host disease (GvHD), the major complication of HSCT. Success-
ful allogeneic HSCT, however, depends also on T-cell mediated
graft-versus-leukemia (GvL) effect, in which donor-derived T
cells clear the remaining leukemic cells in patient. In addition
to alloreactive T cells, donor-derived natural killer (NK) cells,
are able to kill these malignant or virus-infected cells in the
patient. NK cells might therefore have a crucial role in relapse
prevention by destroying remaining acute myeloblastic leukemia
cells (2, 3).
Natural killer cells are regulated by their surface receptors,
which have either activating or inhibitory function by interact-
ing with MHC class I molecules, i.e., group 1 and group 2 HLA-C
alleles and Bw4 alleles, present on normal cell surface. Activa-
tion occur when the NK cell receives a signal from the killer-cell
immunoglobulin-like receptors (KIR) that recognize affected or
tumor cell lacking the normal HLA structures on its surface. The
ratio of activating and inhibitory receptors on the NK cell surface
determines how easily NK cell is activated (4).
Killer-cell immunoglobulin-like receptors are genetically highly
polymorphic and are expressed in a stochastic manner. The HLA
and KIR genes are located in the different chromosomes and
are therefore inherited independently. Consequently, many people
may have activating and/or inhibitory KIR genes for which they
do not have the HLA ligands. Only minority of HLA-matched
donor-patient pairs have the same KIR haplotypes and in case of
HLA-matched siblings, KIR haplotype identity occurs in 25% of
donor-patient pairs (5). Seventeen of the KIR genes can be cat-
egorized for the inhibitory (KIR A-haplotype) or the activating
haplotypes (KIR B haplotype) based on their gene content (6).
These haplotypes can be further divided as telomeric and cen-
tromeric parts, which contain either A- or B-motifs according to
the presence or absence of A- or B-haplotype defining KIR genes
(Figure 1).
The first evidence of the role of the KIR genes in HSCT
came from haploidentical transplantation studies by Ruggeri et al.
They showed that acute myeloid leukemia (AML) patients ben-
efit from the KIR-ligand mismatch due to the “missing self”
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FIGURE 1 |The KIR locus in chromosome 19 is part of the leukocyte
receptor complex (LRC) region and is composed of centromeric and
telomeric parts. The two parts are separated by a recombination site (RS)
sequence. B-haplotype defining genes are depicted in green color, and
A-haplotype defining genes are depicted in yellow color. The framework
genes that are present in each haplotype are blue.
Table 1 | Altogether, 134 patients with 6 diagnoses were included in statistical analysis.
Diagnosis No. of patients Relapse aGvHD grade II–IV Graft type Disease status
PB BM Good prognosis Bad prognosis
AML 47 14 11 15 32 33 14
MDS 16 5 2 3 13 6 10
CML 31 9 10 7 24 20 11
CLL/NHL 13 1 2 5 8 9 4
ALL 27 8 5 7 20 19 8
Total 134 37 30 37 97 87 47
Diagnoses were: acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), chronic lymphoid leukemia (CLL), non-Hodgkin
lymphoma (NHL), acute lymphoid leukemia ALL. Graft types used were peripheral blood (PB) or bone marrow (BM).
phenomenon (7, 8). In addition, there is evidence that the risk
of relapse is reduced in those AML patients whose donors have
several activating KIR genes or KIR-B gene-motifs in unrelated
donor (URD) HSCT (9, 10). However, there are also some con-
flicting results (10–12). Clinical benefits have been speculated to
be gained in settings, where donor NK cells have at least one
inhibitory KIR gene for which they lack the specific HLA class
I ligand (13).
In the present study, we looked if activating KIR genes in the
HLA-matched related donors (RD) have any effect on relapse
incidence or rate in transplanted patients. Altogether, 134 HLA-
matched related sibling pairs were included in this study. We
further focused the AML patients and their donors as the number
of patients with other diagnosis was low and the most promising
results about KIR genes or KIR ligands have been observed in the
AML patients. The clinical data were compared with the presence
or absence of single KIR genes and with the KIR B-content score.
Our results support previous findings that donors with KIR B-
haplotype defining genes contribute the GvL effect resulting in a
lower relapse incidence in AML patients after HSCT.
MATERIALS AND METHODS
PATIENTS
Altogether, 134 adult patients who had undergone related donor
HSCT and their donors were included into this study. Patient
cohort consisted of 6 different diagnoses; 47 patients had AML
(Table 1). Transplantations were performed in Helsinki Univer-
sity Central Hospital Hematology Clinic, Helsinki, Finland, dur-
ing 1993–2004. The set of patients is basically identical to that
described in our previous studies (14, 15). Informed consent was
obtained from all subjects and the study protocol was approved by




All patients and donors were typed for HLA-A, -B, -C, -DRB1, and
-DQB1 using EFI accredited typing methods in routine typing
of the transplantation candidates either by serological method
(Lymphotype HLA-AB and Lymphotype HLA-DR-DQ, Bio-Rad
Medical Diagnostics, Dreieich, Germany) or by using PCR-based
typing methods using the LIPA HLA-C reverse dot blot kit (Inno-
genetics Group, Gent, Belgium), or the Pel Freez HLA-C SSP kits
(Dynal Biotech LLC, Oslo, Norway), or the LABType SSO HLA
typing Test (One Lambda Inc., 21001 Kittridge Street, Canoga
Park, CA 91303-2801, USA). Only 10/10 HLA-matched siblings
were included in the study.
KIR genotyping
Samples were whole genome amplified by using the GenomiPhi
V2 DNA Amplification Kit (GE Healthcare UK Ltd., Chalfont,
Bucks, UK). The amplified DNA samples from the donors were
KIR genotyped by using the LABType SSO KIR typing Test (One
Lambda Inc., 21001 Kittridge Street, Canoga Park, CA 91303-2801,
USA) according to the manufacturer’s instructions or in some
cases by using Olerup SSP® KIR Genotyping kit (Olerup SSP AB,
Stockholm, Sweden).
STATISTICAL ANALYSIS
The incidence of the relapse was compared with the presence or
absence of single KIR genes and with the KIR B-content score
(IPD KIR sequence database, EBI, B-content calculator) within
each diagnosis category. The Log-rank (Peto) and the Wilcoxon
tests were used for the statistical analysis by using the Stats-
Direct software (StatsDirect Ltd. 9 Bonville Chase, Altrincham
Cheshire, UK).
Also, time to relapse was analyzed in survival analyses using
Kaplan–Meier and Cox regression analyses.
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RESULTS
In this study, we looked if activating KIR genes in the HLA-
matched RD have any effect on relapse rate in transplanted
patients. The KIR-B-content score and single KIR genes were eval-
uated against relapse both in the whole patient cohort and within
each diagnosis category.
Statistical significance for better relapse-free survival (log-rank
p-value of 0.059 in Kaplan–Meier) was observed for AML patients
whose donor had KIR2DS2 or KIR2DL2 (Figure 2). This effect was
even strengthened when other factors affecting relapse (a/cGvHD,
FIGURE 2 |Time from transplantation to relapse among patients with
AML (n=47) is shown. Patients whose donors have either KIR2DL2 or
KIR2DS2 (n=19, green line) have lower risk for relapse (log-rank p-value
0.059) than patients whose donors do not have those B haplotype defining
KIR genes (n=28, blue line).
graft type, disease status, GvHD prevention) were included in the
analyses (Cox regression p= 0.015, Table 2). Graft type and disease
status also had an effect on the relapse rate as expected (p= 0.050
and 0.014, respectively). Longer relapse-free survival was observed
in the patients receiving peripheral blood stem cells compared
to the patients receiving bone marrow and also in the patients
with good prognosis compared to the patients with bad progno-
sis. No significant P-values were observed for other KIR genes or
diagnoses.
Statistical significance was not reached when the donor KIR-B-
content score was evaluated in AML patients, but a trend between
high KIR-B-content score and low relapse rate could be seen
(Log-rank P = 0.39, Wilcoxon P = 0.39, data not shown).
If all the patients with different diagnoses were included in the
tests, the statistical significance or trend was lost both in single
gene analysis and B-content score analysis. The frequencies of KIR
genes in the donors were similar to those reported earlier (16).
DISCUSSION
HLA matching is a prerequisite for the successful HSCT and is
the most important factor that is taken into account before trans-
plantation. There is increasing evidence that also other genes of
the genome like KIR genes and minor histocompatibility antigens
(mHAs) (17–19) contribute to the outcome. The effect of the KIR
genes has been studied in different settings where either related or
URDs were used for either T-cell depleted or repleted patients (7,
9, 20–22).
Ruggeri et al. demonstrated an advantageous effect on the
survival of the AML patients in the KIR-ligand mismatched hap-
loidentical transplantation in which the donor NK cell recognition
of the missing self on the recipient targets is associated with
the GvL effect. The positive effect on the survival of the AML
patients was also observed in URD transplantations when the
KIR genes were grouped according to the number of the activat-
ing and inhibitory KIR genes. Donors with more activating KIR
genes (KIR B-haplotype) had more GvL effect than the donors
with inhibitory KIR genes (KIR A-haplotype). The greater the
KIR B-score was, the less relapses were observed (9). As there are
as many as 17 KIR genes that form different haplotypes and as
each of them has the different ligand specificity, the mechanism
how these parameters act together in a beneficial manner must be
complex.
Table 2 | Multivariate Cox regression analyses of relapse rate in AML patients.
B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
KIR2DL2_or_2DS2 −2.038 0.838 5.917 1 0.015 0.130 0.025 0.673
aGvHD 0.141 0.859 0.027 1 0.870 1.151 0.214 6.196
cGvHD −0.005 0.117 0.002 1 0.968 0.995 0.791 1.253
Graft_type 1.718 0.878 3.831 1 0.050 5.575 0.998 31.150
GvHD prevention 1.214 1.152 1.110 1 0.292 3.366 0.352 32.210
Disease status 2.299 0.937 6.022 1 0.014 9.968 1.589 62.546
Presence of donor KIR2DL2 and KIR2DS2 as well as good prognosis and using bone marrow as stem cell source has a beneficial influence on patients’ relapse-free
survival.
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In this study, donor KIR2DS2 and KIR2DL2 that are KIR
B-haplotype defining genes, were associated with the longer
relapse-free survival of AML patients. It seems that the donors
with KIR B-haplotype defining genes may protect patients against
relapse especially in myeloblastic leukemias compared to the
donors without or with only few activating KIR genes. The
enhanced GvL effect was even strengthened when other relapse-
affecting factors such as graft type and disease status were included
in multivariate analyses. As a/cGvHD or GvHD prevention did
not seem to affect the incidence of relapse, it is possible that bio-
logical agents that are involved in these phenomena are different
from the GvL. These results together with Cooley et al. suggest
that selecting donors with KIR-B haplotype defining genes may
be beneficial in different transplantation settings since our study
comprised fully matched RD and Cooley et al. studied registry
donors. In addition, there is evidence that donors with several
activating KIR genes protect patients from the CMV activation
after HSCT (23–25) although in some studies no beneficial effect
was observed (10, 26).
It must be noted that the P values in our study are influenced
by the small sample size as 134 patients represented 6 different
diagnoses and several different KIR genes exist in human genome
and therefore studies with larger cohort are needed. Our results
support, however, the observation that selecting the donors with
more KIR B-haplotype defining genes may lower the risk of relapse
in HSCT. Taking the KIR genotype or KIR-ligand mismatch into
account in donor selection may have a beneficial effect on the
patients’ survival and at least is a valuable tool in risk assessment in
any transplantation setting. However, the downside of the select-
ing donors with high KIR B-content score and/or appropriate KIR
ligand is the increased incidence of the GvHD, the life threatening
condition (27, 28).
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